Our study suggests that patients with diabetes taking SGLT2 inhibitors can reduce the 17% risk of arrhythmias development compared with non-SGLT2 inhibitor users, which may be the possible cause of decreasing the risk of hHF observed in current trials. The gene discussed is SLC5A2; the disease is diabetes mellitus.